1-3 of 3
Janice Lu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups

Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz, Phillipe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4299–4309.
https://doi.org/10.1158/1078-0432.CCR-24-1073
Published: 01 October 2024
View article titled, Elacestrant in ER<sup>+</sup>, HER2<sup>−</sup> Metastatic Breast Cancer with <em>ESR1</em>-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Open the PDF for Elacestrant in ER<sup>+</sup>, HER2<sup>−</sup> Metastatic Breast Cancer with <em>ESR1</em>-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M. Wallace, Henry Kaplan, Lajos Pusztai, David Euhus, Rita Nanda, Anthony D. Elias, Amy S. Clark, Constantine Godellas, Judy C. Boughey, Claudine Isaacs, Debu Tripathy, Janice Lu, Rachel L. Yung, Rosa I. Gallagher, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Gregor Krings, Yunn Yi Chen, David A. Potter, Erica Stringer-Reasor, Sarah Blair, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Adam L. Asare, Jeffrey B. Matthews, Angela M. DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van't Veer, Douglas Yee, Donald A. Berry, Laura J. Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 729–740.
https://doi.org/10.1158/1078-0432.CCR-22-2256
Published: 16 February 2024
View article titled, Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Open the PDF for Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View article titled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data